Business
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay in "DETECSEPS", a real-world evaluation of early detection of sepsis. DETECSEPS Consortium was awarded winner of the "Challenge Prevention" call for proposals launched by the French Health Innovation Agency and operated by the Banque Publique d'Investissement, as part of the France 2030 plan, during the official ceremony held yesterday, December
About this update from Revvity, Inc.
[{"type":"text","content":"HENDERSON, Nev., Dec. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay in "DETECSEPS", a real-world evaluation of early detection of sepsis. DETECSEPS Consortium was awarded winner of the "Challenge Prevention" call for proposals launched by the French Health Innovation Agency and operated by the Banque Publique d'Investissement, as part of the France 2030 plan, during the official ceremony held yesterday, December 3, in Paris, France. This consortium will be financed with approximately €6.3 million (~$7.3 million) by the French government and is a key national strategic axis. As industry partners, Volition (XASE:VNRX) will provide the sole biomarker and Euroimmun, part of Revvity, will provide the Immunodiagnostic Systems (IDS) i10® automated analyzer.","length":924,"tagName":"p"},{"id":"L7y5RjpsZQg","subtype":"videoIframe","type":"youtube","url":"https://www.youtube.com/embed/L7y5RjpsZQg","width":560,"height":315,"anchorId":"7e5c961d-dbbc-59fa-aba4-0630a8c083ff"},{"type":"text","content":"Professor Sébastien Beaune, Emergency Department, IHU SEPSIS, Ambroise Paré Hospital (AP-HP) and Coordinating Investigator of DECTECSEPS program commented:","length":155,"tagName":"p"},{"type":"text","content":""DETECSEPS aims to significantly contribute to reducing the socio-economic burden of sepsis by proposing a radical change in the emergency care pathway for patients with an infection and at risk of progressing to sepsis.","length":225,"tagName":"p"},{"type":"text","content":""Sepsis carries a heavy social, economic and health burden worldwide; there are approximately 166 million cases worldwide resulting in 21.4 million deaths in 20211. Moreover, even survivors of sepsis go on to have significant health problems with 33% mortality within one year, 40% of survivors being re-admitted to hospital within 90 days of discharge and one sixth of survivors experiencing significant morbidity such as functional limitations.","length":451,"tagName":"p"},{"type":"text","content":""Early detection of sepsis in people with an infection and at risk of deteriorating is likely to have favorable public health impact."","length":144,"tagName":"p"},{"type":"text","content":"Prof...